A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

NCT02539225 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

191

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Ramucirumab
DRUG: Placebo
DRUG: S-1
DRUG: Oxaliplatin
DRUG: Paclitaxel

Sponsor

Eli Lilly and Company